Anavex Life Sciences Corp (AVXL)

[bas2020]

Patents have already been granted for 2-73 and 3-71.

2-73: U.S. Pat. No. 9,180,106 granted on 10/21/2015
SIGMA RECEPTORS LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES, OVER CELLULAR MECHANISMS, EXHIBITING PROTOTYPICAL CYTOPROTECTIVE AND ALSO ANTI-CANCER ACTIVITY.

3-71: U.S. Pat. No. 8,673,931
The composition and method Patent covers ANAVEX 3-71 (formerly AF710B) for treating Alzheimer’s disease (AD), type 2 diabetes and insulin resistance. ANAVEX obtained exclusive rights to worldwide patents and patent applications for ANAVEX 3-71 and related compounds in March 2014 from Life Science Research Israel, a subsidiary of the Israel Institute for Biological Research. The Patent has a term that expires no earlier than April 29, 2030.